Mineralys Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Mineralys Therapeutics şirketinin toplam hissedar öz sermayesi $236.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $268.3M ve $31.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$263.60m
Eşitlik	US$236.93m
Toplam yükümlülükler	US$31.32m
Toplam varlıklar	US$268.25m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

Oct 07

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jun 06

We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

Nov 12

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jul 03

Recent updates

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

Oct 07

Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

Sep 17

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jun 06

Mineralys Therapeutics: A Story To Keep An Eye On

Mar 18

Mineralys: 2nd Half 2024 Hypertension Data Readout

Feb 09

We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

Nov 12

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Jul 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MLYS 'nin kısa vadeli varlıkları ( $267.7M ) kısa vadeli yükümlülüklerini ( $31.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: MLYS un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MLYS borçsuzdur.

Borcun Azaltılması: MLYS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MLYS şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: MLYS serbest nakit akışı her yıl % 58.5 1.1 yıl yetecek nakit akışına sahip olacaktır.

Mineralys Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Recent updates

Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Medical Officer notifies of intention to sell stock

Mineralys Therapeutics, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

CEO & Director notifies of intention to sell stock

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

Mineralys Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

CEO & Director notifies of intention to sell stock

Mineralys Therapeutics, Inc. Announces Changes to its Board

CFO & Secretary notifies of intention to sell stock

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Mineralys Therapeutics, Inc., Annual General Meeting, May 22, 2024

Mineralys Therapeutics, Inc. Announces Alexander Asam Informs That His Decision Not to Stand for Re-Election to the Board

Mineralys Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Mineralys Therapeutics: A Story To Keep An Eye On

Mineralys Therapeutics, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Mineralys: 2nd Half 2024 Hypertension Data Readout

Mineralys Therapeutics, Inc. announced that it expects to receive $119.999925 million in funding from TCG Crossover Management, LLC, OrbiMed Advisors LLC, RA Capital Management, L.P., Samsara BioCapital LLC

Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics, Inc Presents Data from the Target-HTN Phase 2 Trial That Further Defines an Endotype-Specific Targeted Approach for Treating Uncontrolled or Resistant Hypertension with Lorundrostat

We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely

New minor risk - Share price stability

Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Mineralys Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Mineralys Therapeutics, Inc. Expands Its Board

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session At 2023 Aha Hypertension Scientific Sessions

Mineralys Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics, Inc. Doses the First Patient in the Advanceance-Htn Pivotal Trial

Mineralys Therapeutics, Inc. has completed an IPO in the amount of $192 million.

Mineralys Therapeutics, Inc. has completed an IPO in the amount of $192 million.

High number of new and inexperienced directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin